Biotech Values

[DewDiligence]

ADXS acquires AYLA in all-stock deal tantamount to a reverse merger (and will be recorded as such in the “Biotech Buyouts” table in the intro section of this message board):

https://www.globenewswire.com/news-release/2022/10/19/2537180/0/en/Ayala-Pharmaceuticals-and-Advaxis-Enter-into-Merger-Agreement.html

Upon completion of the merger, Ayala stockholders will own approximately 62.5% of the combined company’s outstanding common stock and Advaxis stockholders will own approximately 37.5%, subject to the terms of the merger agreement.

ADXS should have done a deal like this several years ago, before diluting shareholders into oblivion, although the end result might have been no different.